Cidara Therapeutics, Inc.
CDTX
Classificação em ações
#3185
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Preço da ação
$221.38
Última sincronização: 2026-01-08
Valor de mercado
$5.61B
Variação (1 dia)
0.00%
Variação (1 ano)
118.07%
País
US
Negociar Cidara Therapeutics, Inc. (CDTX)
Categoria
Healthcare
Lucros da Cidara Therapeutics, Inc. (CDTX)
Lucros em Sep 2025 TTM: $-184.80M
De acordo com os últimos relatórios financeiros da Cidara Therapeutics, Inc., os ganhos atuais da empresa são de $-184.80M. Em 2023, a empresa teve ganhos de $-25.07M, um aumento em relação a aos ganhos de 2022, que foram de $-33.31M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Cidara Therapeutics, Inc. de 2012 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-184.80M | 8.52% |
| 2024 | $-170.29M | 579.40% |
| 2023 | $-25.07M | -24.76% |
| 2022 | $-33.31M | -21.56% |
| 2021 | $-42.47M | -41.11% |
| 2020 | $-72.11M | 75.49% |
| 2019 | $-41.09M | -30.37% |
| 2018 | $-59.02M | 5.90% |
| 2017 | $-55.73M | 15.70% |
| 2016 | $-48.17M | 49.61% |
| 2015 | $-32.19M | 170.67% |
| 2014 | $-11.89M | 784.97% |
| 2013 | $-1.34M | 69.70% |
| 2012 | $-792.00K | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -2,954.38% |
US
|
|
| $-3.09B | 1,570.45% |
US
|
|
| $-4.02B | 2,073.27% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,155.55% |
NL
|
